News & Updates

The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.

Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.

Treatment with the novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα) pemafibrate appears to produce a significant reduction in liver stiffness but not in liver fat content in patients with high-risk nonalcoholic fatty liver disease (NAFLD), according to the results of a phase II trial.

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

In individuals with type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide appeared to yield a cardioprotective benefit, data from the secondary endpoint analysis of the LIRAFLAME* trial suggests.

Women on menopausal hormone therapy are at risk of developing hypertension, particularly those using oral oestrogen plus a progestogen such as pregnane and norpregnane derivatives, according to a study.

Among women receiving immunosuppression treatment with mammalian target of rapamycin inhibitors (mTORi), the incidence of ovarian cyst appears to be a common adverse event, according to the results of a systematic review and meta-analysis.

Extending treatment with letrozole for 5 years improves disease-free survival (DFS) rates in postmenopausal women with early-stage breast cancer who have already received tamoxifen for 2–3 years, according to the GIM4* trial.